Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Imunon, Inc. (IMNN)
Company Research
Source: GlobeNewswire
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces positive results from a live virus challenge study conducted for IMUNON by the Wistar Institute with IMNN-101 against the SARS-CoV-2 variant XBB.1.5. This study was conducted using the clinical vector that IMUNON intends to bring into its Phase 1 study during the second quarter and showed IMNN-101 immunogenicity and protective activity in a live viral mouse challenge. The SARS-CoV-2 XBB.1.5 variant was declared as the variant of concern for the 2023-2024 vaccine by the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee. IMNN-101 is formulated with a synthetic DNA d
Show less
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 [Yahoo! Finance]Yahoo! Finance
- IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101GlobeNewswire
- IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine… [Yahoo! Finance]Yahoo! Finance
- IMUNON Reports Compliance with Nasdaq Listing Requirements [Yahoo! Finance]Yahoo! Finance
- IMUNON Reports Compliance with Nasdaq Listing RequirementsGlobeNewswire
IMNN
Analyst Actions
- 3/18/24 - HC Wainwright
IMNN
Sec Filings
- 4/29/24 - Form ARS
- 4/26/24 - Form DEF
- 4/11/24 - Form 8-K
- IMNN's page on the SEC website